JTO Clinical and Research Reports最新文献

{"title":"Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief Report","authors":"Adele Bonato MD ,&nbsp;Claudia Parisi MD ,&nbsp;Priscilla Cascetta MD ,&nbsp;Anna Reni MD ,&nbsp;May-Lucie Meyer MD ,&nbsp;Mariona Riudavets MD, PhD ,&nbsp;David Planchard MD, PhD ,&nbsp;Benjamin Besse MD, PhD ,&nbsp;Jordi Remon MD ,&nbsp;Francesco Facchinetti MD, PhD ,&nbsp;Lorenzo Belluomini MD, PhD ,&nbsp;Lisa Derosa MD, PhD ,&nbsp;Fabrice Barlesi MD, PhD","doi":"10.1016/j.jtocrr.2025.100928","DOIUrl":"10.1016/j.jtocrr.2025.100928","url":null,"abstract":"<div><h3>Background</h3><div>Although most phase III pivotal trials have set the duration of immune checkpoint blockers (ICB) for advanced NSCLC at 2 years, the criteria for safely discontinuing ICB remain undefined. Growing evidence links ICB efficacy to gut microbiota, positioning gut microbial taxonomic profiling as a promising biomarker to guide treatment decisions. We performed a retrospective analysis exploring clinical outcomes and the utility of multiomic decision-making tools in patients with NSCLC at Gustave Roussy who completed 24 months of ICB-based therapy without disease progression (PD).</div></div><div><h3>Methods</h3><div>Patients receiving ICB between July 2016 and January 2023 were identified from the ONCOBIOTICS (NCT04567446) and STING (NCT04932525) study datasets. We selected those who reached 24 months of treatment without disease progression. Clinical characteristics and multiomic assessments, including gut microbiota profiling (TOPOSCORE by whole-genome sequencing), positron emission tomography–18-fluorodeoxyglucose imaging, and circulating tumor DNA, collected at 24 months, were analyzed. Key outcomes included overall survival (OS), progression-free survival (PFS), and PFS rates at 24 months after the completion of 2 years of ICB, stratified by molecular, metabolic, and microbial signatures.</div></div><div><h3>Results</h3><div>Out of 123 patients treated for at least 18 months, 35 completed 24 months, with 31 eligible for the analysis. Of these, 68% continued ICB, whereas 32% discontinued therapy at the physician’s decision. Clinical characteristics were similar across groups. After a median follow-up of 59.1 months, OS and PFS did not differ significantly between those who discontinued and those who continued treatment (OS <em>p</em> = 0.9012). Among all multiomic tools, gut microbiota composition exhibited a trend (though not statistically significant) association with PFS rates at 24 months after the completion of 2 years of ICB. Patients with a favorable microbiota profile had a higher rate of sustained response at 24 months compared with those with dysbiotic signatures (81% versus 44%, respectively, <em>p</em> = 0.0870).</div></div><div><h3>Conclusions</h3><div>Discontinuing ICB after 24 months did not negatively impact OS in our real-world cohort. Although limited by the small sample size, these findings support the potential of gut microbiota profiling as a promising tool to guide ICB duration. Integrating a translational multiomic algorithm, in particular microbial signals, may help personalize treatment strategies and safely shorten immunotherapy courses.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 1","pages":"Article 100928"},"PeriodicalIF":3.5,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145798012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curative-Intent Multimodality Treatment for NSCLC: Will Global Healthcare Systems Rise to the Challenge? A Perspective From the United Kingdom","authors":"Matthew Evison MD, MRCP ,&nbsp;Shobhit Baijal MBBS, BSc (Hons) ,&nbsp;Mayuri Basnet MBBS, FRCPath ,&nbsp;Tim Batchelor MSc, FRCS (CTh) ,&nbsp;Karen Clayton MSc ACP ,&nbsp;Lorraine Dallas BA ,&nbsp;Alastair Greystoke PhD ,&nbsp;Adam Januszewski PhD ,&nbsp;Neal Navani PhD ,&nbsp;Riyaz Shah PhD ,&nbsp;Annabel Sharkey PhD, FRCS (CTh) ,&nbsp;Jyotika Singh MBA","doi":"10.1016/j.jtocrr.2025.100923","DOIUrl":"10.1016/j.jtocrr.2025.100923","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 2","pages":"Article 100923"},"PeriodicalIF":3.5,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146024149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA)","authors":"Grace Chazan FRACP ,&nbsp;Marliese Alexander PhD ,&nbsp;Fanny Franchini PhD ,&nbsp;Maarten IJzerman PhD ,&nbsp;Roma Shah MPH ,&nbsp;Ani John PhD ,&nbsp;Tim Spelman PhD ,&nbsp;Malinda Itchins PhD ,&nbsp;Nick Pavlakis PhD ,&nbsp;Adnan Nagrial PhD ,&nbsp;Lydia Warburton FRACP ,&nbsp;Samantha Bowyer FRACP ,&nbsp;Steven Kao PhD ,&nbsp;Sagun Parakh PhD ,&nbsp;Benjamin J. Solomon PhD","doi":"10.1016/j.jtocrr.2025.100924","DOIUrl":"10.1016/j.jtocrr.2025.100924","url":null,"abstract":"<div><h3>Introduction</h3><div>Advanced lung cancer has historically been associated with poor survival. However, with the advent of targeted therapies, outcomes are improving. Among patients with <em>ALK-</em>rearranged advanced NSCLC (ALK+ aNSCLC), real-world data on treatment patterns, prognostic factors, and survival in the era of contemporary therapy remain limited.</div></div><div><h3>Methods</h3><div>We conducted a retrospective observational cohort study using deidentified patient, disease, and outcomes data from the AUstralasian thoRacic cancers lOngitudinal cohoRt study and biobAnk (AURORA; ACTRN12625000038493). Eligible patients were diagnosed with ALK+ aNSCLC between 2006 and 2025.</div></div><div><h3>Results</h3><div>Of the 4776 patients with thoracic malignancies enrolled across eight sites (as of April 2025), 218 met the inclusion criteria—the largest reported Australian cohort of ALK+ aNSCLC. All patients were treated in academic centers. The median age was 55 years; 54% were female, 66% were never-smokers, and 41% had participated in a clinical trial. The median overall survival was 90.8 months (95% CI: 69.8–not reached). Nearly all patients (99%) received an ALK inhibitor; 83% in the first-line setting. Treatment sequences evolved over time. Most (68%) received at least two lines of therapy; 21% received 4 or more lines. Smoking status, age, and Eastern Cooperative Oncology Group Performance Status were prognostically associated with survival.</div></div><div><h3>Conclusion</h3><div>This study highlights the remarkable survival achievable in the real-world setting for some patients with ALK+ aNSCLC, compared with historical cohorts. Several clinical factors associated with survival were identified. Larger studies are needed to investigate how treatment sequences may be optimized to further improve survival outcomes.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 2","pages":"Article 100924"},"PeriodicalIF":3.5,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146024079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Added Value of Genome-Wide Copy Numbers to Objectively Resolve Clonality of Multiple Tumors With Pulmonary Involvement and Ambiguous or Inconclusive Mutational Diagnosis","authors":"Jurriaan Janssen MSc ,&nbsp;Bárbara Andrade Barbosa MSc ,&nbsp;Tim R. Mocking MSc ,&nbsp;Hendrik F. van Essen MA ,&nbsp;Paul P. Eijk BSc ,&nbsp;Jacqueline Egthuijsen BSc ,&nbsp;Anabela Ferro PhD ,&nbsp;Jose-Pedro Parracha de Matos MSc ,&nbsp;Swip Draijer PhD ,&nbsp;Albrecht Stenzinger Dr. (Prof.) ,&nbsp;Anke van den Berg Dr. (Prof.) ,&nbsp;José Carlos Machado Dr. (Prof.) ,&nbsp;Erik Thunnissen PhD ,&nbsp;Yongsoo Kim PhD ,&nbsp;Teodora Radonic PhD ,&nbsp;Bauke Ylstra Dr. (Prof.)","doi":"10.1016/j.jtocrr.2025.100921","DOIUrl":"10.1016/j.jtocrr.2025.100921","url":null,"abstract":"<div><h3>Introduction</h3><div>The incidence of patients presenting with multiple cancers (MCs) and pulmonary involvement is increasing. Although next-generation sequencing mutation panels can discern metastases (clonal) from separate primary cancers (nonclonal), it does not warrant a reliable diagnosis for all patients despite significant therapeutic implications. We evaluated the added value of genome-wide copy number aberrations (CNAs) for clonality diagnosis.</div></div><div><h3>Methods</h3><div>Two cohorts were assembled: 41 clonal and 41 nonclonal pairs from the TRACERx cohort and 21 MC pairs that had sufficient DNA for whole-exome sequencing (WES) from 120 patients diagnosed using CNA analysis in our routine pathology practice between 2016 and 2022. Clonality was determined by comparing tumor pairs using (1) WES mutations as a definitive standard, (2) a conventional mutation panel with an adapted 2024 International Association for the Study of Lung Cancer algorithm, and (3) CNAs with log-likelihood ratio and Pearson correlation metrics.</div></div><div><h3>Results</h3><div>All tumor pairs classified as definite “clonal” or “nonclonal” by mutation analysis (TRACERx: 35 of 82 [43%], MC cohort: 6 of 21 [29%]) were in concordance with WES and CNAs. Of the tumor pairs classified as “probable nonclonal” or “inconclusive” by mutation analysis (TRACERx: 47 of 82 [57%], MC cohort: 15 of 21 [71%]), most could be correctly reclassified by CNAs (TRACERx: 46 of 47 [98%], MC cohort: 15 of 16 [94%]). For each cohort, one tumor pair remained inconclusive. Furthermore, we present a CNA clonality workflow for implementation in molecular diagnostics.</div></div><div><h3>Conclusion</h3><div>Genome-wide CNA analysis provides complementary information to resolve clonality of MCs with ambiguous mutational clonality status, enhancing clinical decision-making.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 12","pages":"Article 100921"},"PeriodicalIF":3.5,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing Global Disparities in Lung Cancer Screening: Lessons From Puerto Rico and Beyond","authors":"Patrick Goodley MBBChir ,&nbsp;Matthew Evison MD","doi":"10.1016/j.jtocrr.2025.100919","DOIUrl":"10.1016/j.jtocrr.2025.100919","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 12","pages":"Article 100919"},"PeriodicalIF":3.5,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC","authors":"Beatriz Jimenez Munarriz MD ,&nbsp;Sameena Khan MBChB, PhD ,&nbsp;Katrina Hueniken MPH, MSc ,&nbsp;Shirley Tam MD ,&nbsp;Devalben Patel BSc, MLT ,&nbsp;Luna Zhan MPH ,&nbsp;Catherine Brown MSc ,&nbsp;Lawson Eng MD, SM, FRCPC ,&nbsp;Adrian Sacher MMSc, MD ,&nbsp;Penelope Bradbury MB, BCh, FRACP, MD ,&nbsp;Natasha Leighl MMSc, MD, BSc ,&nbsp;Geoffrey Liu MSc, MD ,&nbsp;Frances A. Shepherd MD, FRCPC","doi":"10.1016/j.jtocrr.2025.100918","DOIUrl":"10.1016/j.jtocrr.2025.100918","url":null,"abstract":"<div><h3>Introduction</h3><div>ALK tyrosine kinase inhibitors (ALK TKIs) are started at a standard dose regardless of patients’ weight and body surface area (BSA). In this retrospective analysis, the authors explored whether body size variables were associated with toxicity and efficacy.</div></div><div><h3>Methods</h3><div>Retrospective data for <em>ALK-</em>positive patients at the Princess Margaret Cancer Centre were extracted from electronic health records. Associations between BSA/weight quartiles and dose reductions (DRs), temporary interruptions (TIs), and permanent discontinuation due to toxicity were evaluated using generalized linear mixed modeling. Survival analysis was conducted using Kaplan-Meier curves and log-rank tests.</div></div><div><h3>Results</h3><div>Among 142 patients with <em>ALK</em>-positive NSCLC treated between July 2012 and March 2024, the median age was 58 years, 54% were female, 78% never-smokers, 49% were Asian, and 37% were Caucasian. A significantly higher proportion of males were in the highest BSA Q4 (89%, <em>p</em> &lt; 0.001), whereas more females (91%, <em>p</em> &lt; 0.001) and Asians were in the lowest BSA Q1 (80%, <em>p</em> &lt; 0.001).</div><div>Higher weight at ALK TKI initiation was associated with an increased likelihood of DR at any time (adjusted odds ratio [aOR] = 1.20 per 10-kg increase, 95% confidence interval: 1.0–1.4, <em>p =</em> 0.04), as was having higher BSA (aOR = 2.00 per 0.5-U increase, 95% confidence interval: 1.0–3.9, <em>p =</em> 0.04). TIs were associated with higher weight (10-kg increase, aOR = 1.28, <em>p =</em> 0.006), BMI (5-U BMI increase, aOR = 1.40, <em>p =</em> 0.02), and BSA (0.5-U increase, aOR = 2.59, <em>p =</em> 0.005). These weight/BSA results were statistically significant in patients during alectinib or lorlatinib treatment. In contrast, permanent discontinuation was associated with higher weight/BSA in brigatinib/ceritinib/crizotinib-treated patients. In multivariable analysis, older age and male sex were independently associated with more DRs and TIs. Weight and BSA quartiles were not associated with progression-free survival (<em>p =</em> 0.4) or overall survival (<em>p =</em> 0.6).</div></div><div><h3>Conclusions</h3><div>Higher weight and larger BSA at the start of ALK TKI treatment were associated with higher likelihood of toxicity, leading to more DRs and TIs—particularly in males and patients receiving alectinib and lorlatinib. However, weight and BSA were not associated with treatment outcomes.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"7 1","pages":"Article 100918"},"PeriodicalIF":3.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145734620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid-onset Severe Cytokine Release Syndrome With Marked Interleukin-6 Increase and Acute Liver Injury After the First Tarlatamab Dose in SCLC: Case Report","authors":"Kento Takagi MD ,&nbsp;Go Saito MD, PhD ,&nbsp;Toshiaki Inazaki MD ,&nbsp;Hikaru Shojima MD ,&nbsp;Jun Miyakoshi MD ,&nbsp;Akira Naito MD, PhD ,&nbsp;Shun Sato MD, PhD ,&nbsp;Takashi Shimazui MD, PhD ,&nbsp;Haruka Anzai MD ,&nbsp;Chiaki Imai PhD ,&nbsp;Takuji Suzuki MD, PhD","doi":"10.1016/j.jtocrr.2025.100917","DOIUrl":"10.1016/j.jtocrr.2025.100917","url":null,"abstract":"<div><div>Tarlatamab is a novel bispecific T-cell engager therapy with promising efficacy in patients with previously treated extensive-stage SCLC. Cytokine release syndrome (CRS) is the most common adverse event related to tarlatamab, although severe CRS remains rare, and grade 3 or higher adverse events have been reported to be less common with tarlatamab than with chemotherapy. Available clinical data on severe adverse events associated with tarlatamab remain limited. Herein, we report a case of a 55-year-old woman with extensive-stage-SCLC who was treated with tarlatamab. Severe CRS and liver injury rapidly developed in the patient after the first tarlatamab dose, which led to treatment discontinuation. This report also presents the temporal changes in serum interleukin-6 levels, highlighting its potential utility as a biomarker for the onset and severity of CRS.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 12","pages":"Article 100917"},"PeriodicalIF":3.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System–Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes","authors":"Surbhi Singhal MD ,&nbsp;Caressa Hui MD ,&nbsp;Joel W. Neal MD, PhD ,&nbsp;Seema Nagpal MD ,&nbsp;Mohana Roy MD ,&nbsp;Millie Das MD ,&nbsp;Kavitha Ramchandran MD ,&nbsp;Erqi Pollom MD ,&nbsp;Giovanni Selvaggi MD ,&nbsp;Heather A. Wakelee MD ,&nbsp;Nathaniel J. Myall MD","doi":"10.1016/j.jtocrr.2025.100914","DOIUrl":"10.1016/j.jtocrr.2025.100914","url":null,"abstract":"<div><h3>Introduction</h3><div>Central nervous system (CNS) metastases are common in <em>ALK</em>-rearranged NSCLC. The optimal treatment strategy for patients who develop CNS progression during treatment with CNS-penetrable <em>ALK</em> tyrosine kinase inhibitors (TKIs) is unknown. Here, we characterized practice patterns and outcomes for patients who developed CNS progression during treatment with CNS-penetrable TKI.</div></div><div><h3>Methods</h3><div>This retrospective study included patients who developed CNS progression (time 0, [T0]) on alectinib, lorlatinib, brigatinib, or ensartinib. Patients were characterized according to TKI management (i.e., TKI unaltered, TKI-altered [switched TKI or increased TKI dose], TKI discontinued) at T0. Intracranial progression-free survival was evaluated using Kaplan-Meier and compared using the log-rank test.</div></div><div><h3>Results</h3><div>Among 98 patients treated with a CNS-penetrable TKI, 36 (37%) experienced CNS progression. Overall, 33 (92%) developed parenchymal and seven (19%) developed leptomeningeal progression, respectively. At T0, 16 (44%) had TKI unaltered, 14 (39%) had TKI altered (eight switched TKI, six increased TKI dose), and six (17%) discontinued TKI. Patients with TKI-altered tended to have more frequent leptomeningeal disease or concurrent systemic progression at T0. Intracranial radiation was given at T0 in 14 (88%) of TKI-unaltered and three (21%) of TKI-altered patients. The median intracranial progression-free survival from T0 was not significantly different between the TKI-altered versus unaltered groups (<em>p</em> = 0.21).</div></div><div><h3>Conclusions</h3><div>For patients with <em>ALK-</em>rearranged NSCLC with leptomeningeal progression or concurrent systemic progression, TKI change or dose increase was a feasible salvage strategy for CNS progression during treatment with CNS-penetrable TKI.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 12","pages":"Article 100914"},"PeriodicalIF":3.5,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145420517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]","authors":"Marina C. Garassino MD ,&nbsp;Shirish Gadgeel MD ,&nbsp;Silvia Novello MD, PhD ,&nbsp;Balazs Halmos MD ,&nbsp;Enriqueta Felip MD ,&nbsp;Giovanna Speranza MD ,&nbsp;Rina Hui PhD ,&nbsp;Edward B. Garon MD ,&nbsp;Hidehito Horinouchi MD, PhD ,&nbsp;Shunichi Sugawara MD, PhD ,&nbsp;Delvys Rodriguez-Abreu MD, PhD ,&nbsp;Martin Reck MD ,&nbsp;Razvan Cristescu PhD ,&nbsp;Deepti Aurora-Garg PhD ,&nbsp;Andrey Loboda PhD ,&nbsp;Jared Lunceford PhD ,&nbsp;Julie Kobie PhD ,&nbsp;Mark Ayers MS ,&nbsp;Bilal Piperdi MD ,&nbsp;M. Catherine Pietanza MD ,&nbsp;Luis Paz-Ares MD, PhD","doi":"10.1016/j.jtocrr.2025.100892","DOIUrl":"10.1016/j.jtocrr.2025.100892","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 10","pages":"Article 100892"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145220590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable Response to Lenvatinib in Platinum-Refractory Metastatic High-Grade Thymic Mucoepidermoid Carcinoma: A Case Report","authors":"Noa Amin PhD, MRCP ,&nbsp;Thanika Ketpueak DM ,&nbsp;Simon Jordan MBBCh, MD ,&nbsp;Andrew G. Nicholson DM, FRCPath ,&nbsp;Yu Zhi Zhang MBBS, PhD, FRCPath ,&nbsp;Sanjay Popat PhD FRCP","doi":"10.1016/j.jtocrr.2025.100894","DOIUrl":"10.1016/j.jtocrr.2025.100894","url":null,"abstract":"<div><div>Thymic mucoepidermoid carcinoma (MEC) is a rare thymic carcinoma subtype. Current metastatic thymic carcinoma guidelines recommend first-line platinum-based chemotherapy. However, evidence suggests that MECs, including those of the lung and salivary gland, are chemorefractory, highlighting a more nuanced approach to systemic therapy decision-making. Here, we report a case of durable partial response to second-line lenvatinib in a patient with metastatic high-grade thymic MEC, refractory to first-line platinum-based chemotherapy, suggesting a potentially preferred first-line role for lenvatinib for this subtype.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 10","pages":"Article 100894"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145220589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}